Mayne Pharma Group Ltd
ASX:MYX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Galaxy Entertainment Group Ltd
HKEX:27
|
HK |
MYX's latest stock split occurred on Jan 18, 2023
The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.
Before the split, MYX traded at 4.5 per share. Afterward, the share price was about 3.9.
The adjusted shares began trading on Jan 18, 2023. This was MYX's 5th stock split, following the previous one in Jan 17, 2023.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 24, 2026
|
|
Cue Biopharma Inc
NASDAQ:CUE
|
1-for-30
/30
|
0.5542 16.626 USD | 17.695 17.695 USD |
|
Apr 24, 2026
|
|
Medical Data Vision Co Ltd
TSE:3902
|
2-for-7253607
/3626803.5
|
1684 1684 JPY | N/A |
|
Apr 24, 2026
|
T
|
Trillion Energy International Inc
CNSX:TCF
|
1-for-5
/5
|
0.2 0.2 CAD | 0.18 0.18 CAD |
|
Apr 24, 2026
|
E
|
ESGL Holdings Ltd
NASDAQ:ESGL
|
1-for-3
/3
|
2.35 7.05 USD | 2.93 2.93 USD |
|
Apr 24, 2026
|
|
Metro Mining Ltd
ASX:MMI
|
1-for-20
/20
|
0.067 1.34 AUD | 1.3 1.3 AUD |
CUE
3902
MMI
Mayne Pharma Group Ltd
Glance View
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.
